Corteva, Inc. (CTVA)

Price—Loading quote

AI: Fair-priced

Price checkThe shares look fairly priced, with solid growth already built into expectations.

At $76.68, Corteva’s equity was worth about $51.16 billion. Subtracting June net cash of $683 million gives roughly $50.48 billion for the operating business. Against management’s 2026 adjusted earnings guidance of $3.60–$3.80 per share, the price is 20–21 times earnings; against guided operating profit before interest, taxes, depreciation and amortization of $4.1–$4.3 billion, it is about 12 times. Those are reasonable quality-company multiples, but not bargain levels, so the verdict is fair-priced and assumes continued growth after the split.

Big pictureRecent profit growth is encouraging, but sales and cash generation remain uneven.

Sales have been steady rather than compounding: 2025 revenue was $17.40 billion, slightly below 2022’s $17.46 billion. Net income swung from $735 million in 2023 to $1.09 billion in 2025. Free cash flow—cash left after running and investing in the business—was $2.82 billion in 2025, but averaged only about $1.59 billion across 2020–2025 and fell to $267 million in 2022. First-half 2026 sales rose 4% and adjusted operating profit rose 10%, yet weather, crop acreage and distributor timing keep annual cash generation uneven.

Business strengthFinancial risk is low, while buybacks have meaningfully reduced the share count.

At June 2026, cash was $2.37 billion versus $1.68 billion of debt, leaving $683 million of net cash; current assets of $16.36 billion also exceeded current liabilities by $5.57 billion. Corteva spent $1.07 billion on buybacks and $475 million on dividends in 2025, below that year’s $2.82 billion free cash flow. Shares fell from 743.5 million in 2020 to 672.2 million in 2025, a 9.6% reduction rather than dilution. Meanwhile, research spending reached $1.47 billion, supporting future products without stressing the balance sheet.

What could change the storyThe split and product pipeline can unlock value, but crop-protection pricing remains the test.

Second-quarter Seed profit before interest, taxes, depreciation and amortization rose 6% on flat sales, showing pricing, licensing and cost gains. The bull case improves if 2026 profit reaches the $4.3 billion guidance ceiling and free cash flow stays above $2.5 billion. The bear case strengthens if Crop Protection’s 4% quarterly sales decline and 4% price drop persist, especially in Latin America. The October 1 split could sharpen focus, but the price already requires roughly $3.70 of adjusted earnings per share and smooth separation, including only a $25 million 2026 dis-synergy headwind.

$76.68 price considered

AI: News

Mixed quarter triggers selloffQuarterly sales missed expectations even as profit improved, prompting a sharp reassessment of the stock.

On July 30, Corteva reported second-quarter sales of $6.38 billion, down 1%, while adjusted operating earnings rose 5% to $2.30 per share. Management raised full-year adjusted earnings guidance to $3.60–$3.80. Reuters reported a 3.7% after-hours decline as sales missed estimates; Investing.com observed an approximately 8.6% drop the next morning. The timing and reporting associate the reaction with the revenue shortfall and tempered guidance expectations, but do not prove those were the stock’s only drivers.

Vylor split advancesPreparations for the October split advanced, giving investors more clarity about the two future companies.

On August 14, Vylor filed its first amended registration statement, adding business, strategy and historical financial details. An August 6 exchange offer also sought to transfer three note series totaling $1.6 billion to Vylor, contingent on completing the separation. These are concrete steps toward the targeted October 1 spin-off. The split may reveal different values for Seed and Crop Protection, but the board can still change course and final standalone capital structures were not yet approved.

Herbicide pipeline agreementA new herbicide agreement expands Corteva’s pipeline, but meaningful sales remain several years away.

On June 16, Corteva and FMC announced a co-exclusive agreement covering rimisoxafen herbicides for corn and soybeans across the Americas. Corteva committed a $200 million product prepurchase, and both companies will commercialize their own formulations. First sales are expected by the end of the decade, subject to regulatory approvals. The product could help Corteva counter generic pricing with differentiated technology, but the cash payment precedes revenue, undisclosed terms limit valuation, and no reliable immediate stock reaction was established.

Revenue

2018

2019

2020

2021

2022

2023

2024

2025

Net income

2018

2019

2020

2021

2022

2023

2024

2025

Free cash flow

2018

2019

2020

2021

2022

2023

2024

2025

Total cash / debt

CashTotal debt

2018

2019

2020

2021

2022

2023

2024

2025

Financial statements

	2025	2024	2023	2022	2021	2020	2019	2018
Revenue	$17.40B	$16.91B	$17.23B	$17.45B	$15.65B	$14.22B	$13.85B	$14.29B
Research & development	$1.47B	$1.40B	$1.34B	$1.22B	$1.19B	$1.14B	$1.15B	$1.35B
Net income	$1.09B	$907.0M	$735.0M	$1.15B	$1.76B	$681.0M	−$959.0M	−$5.07B
Basic EPSper diluted share	$1.60	$1.31	$1.04	$1.59	$2.39	$0.91	-$1.28	-$6.76
Diluted EPSper diluted share	$1.60	$1.30	$1.03	$1.58	$2.37	$0.91	-$1.28	-$6.76

Review source filings at SEC.gov ↗

Insider buys & sells

Jul 1, 2024–Jun 30, 2026

Buys0$0.00 disclosed value

Sells (SEC code S)7$14.24M disclosed value

Transaction	Insider	Type	Shares	Price	Value	Owned after
Feb 20, 2026Form 4	TITUS BRIANSee Remarks	SellCommon Stock	4.0K	$76.53	$306.1K	8.1K
Feb 20, 2026Form 4	TITUS BRIANSee Remarks	SellCommon Stock	4.3K	$76.57	$330.1K	12.1K
Aug 29, 2025Form 4	King Robert D.EVP, Crop Protection Business	SellCommon Stock	37.3K	$74.20	$2.77M	49.3K
May 13, 2025Form 4	FUERER CORNEL BSee Remarks	SellCommon Stock	55.2K	$68.06	$3.76M	101.6K
Feb 20, 2025Form 4	TITUS BRIANSee Remarks	SellCommon Stock	26.6K	$63.74	$1.69M	11.3K

Review ownership filings at SEC.gov ↗

Corteva, Inc. (CTVA)

Financial charts

Financial statements

Insider buys & sells